Blur
Built by Pharma. For Pharma.

Blur

Life Science Data & Document Anonymization with NLP Automation

Insource innovation with the #1 tool for anonymization and quantifiable risk measurement.  Built in collaboration with enterprise pharmaceutical sponsors, Blur is the efficient solution for scaling anonymization and quantitative risk.  With its user centered design, risk assessment engine and NLP capabilities, Blur is the tool dozens of sponsors have chosen to share clinical data and associated documents consistently.

Now Available Blur 2.4 -  Watch How Blur Streamlines Anonymization?

Official Blur 2.4 release video-2
 

 

Read Case Study

Request a Demo

Blur

Product Features

Insource Blur software into your organization and begin sharing on any scale. Blur offers the following key features:

  • Support for EMA 070, Health Canada, HIPAA, and CDISC standards
  • Transformation recommendations from user set parameters 
  • NLP capabilities to automate sharing tasks
  • UX menu-driven functionality
  • No SAS programming needed
  • Fully authenticated and maintained product
  • Audit trail with built-in workflow review
  • Summarized documentation reports
  • Automated data configuration
  • Structured UI supporting risk simulation

What makes Blur different?

Built in collaboration with sponsors, Blur was designed to meet  internal and external sharing requirements of large pharmaceutical sponsors, balancing sharing aspirations against constraints.  This cooperative approach has led to the design of Blur and its recommendation engine that has propelled Blur to be the most used and trusted tool to accelerate clinical trial sharing. 

The risk engine of Blur allows clients to set their own criteria, which dictates how Blur ranks and provides recommendations for transformation.  With multiple options presented, users can make informed decisions based on quantifiable risk measurements. 

Blur allows sponsors to use the most practical approaches for anonymization; including, anonymization based on study specific population and/or entire therapeutic populations.  To accelerate sharing Blur 2.4 now encompasses NLP capabilities, automating many sharing tasks.  With quarterly releases and Blur User groups, d-wise and our clients continues to invest and influence Blurs roadmap and enhance automation. 

 

 

“We wanted to expand the availability of patient clinical trial data, doing our part to drive medical innovation. Blur is the tool we needed to streamline our processes and maintain the utmost quality of sensitive patient data being released to the public.”- Global Pharmaceutical, Chief Privacy Officer
  • Risk Measurement Complex

  • Agencies Pressure to Anonymize

  • Manual Approaches Not Scalable